A comparison of the bronchodilating effects of salmeterol, salbutamol and Ipratropium bromide in patients with chronic obstructive pulmonary disease

The Addition of Salmeterol 50 µg Bid to Anticholinergenic Treatment in Patients with COPD: A Randomized Placebo Controlled Trial

“…The promising efficacy of salmeterol compared with anticholinergic agents in improving lung function and the symptoms of COPD (17,18), as well as in providing additional benefits in patients already receiving anticholinergic therapy (as shown in our study and previously [9]), may be explained in part by salmeterol's long duration of bronchodilation (29) and in part by additional nonbronchodilator effects of the agent. These include a cytoprotective effect on the epithelium (30), increasing ciliary function (12,13) and protection from infection (30,31).…”

“…Salmeterol has also been found to improve lung function (17,18), reduce dyspnea (17) and increase the time to first COPD exacerbation (17) to a greater extent than the anticholinergic agent ipratropium bromide. There are, however, few data on the benefits of adding salmeterol to a regimen already containing an anticholinergic agent.…”

Inhaled oxitropium bromide is currently used as the first-line therapy of patients with chronic pulmonary disease in Japan

“…Our published data do not support the assumption that elderly patients suffering from COPD are less sensitive to action of b 2 -agonists. In fact, we demonstrated that salmeterol was more potent than ipratropium bromide, although our study population was expressly chosen to include aged patients [12]. We must emphasize that it has been suggested that, whilst the function of b 2 -receptors may become impaired with age, their responsiveness is nonetheless well preserved.…”

Bronchodilator Combination Therapy for the Treatment of Chronic Obstructive Pulmonary Disease

“…The efficacy of salmeterol has also been compared with that of ipratropium [19,21,[25][26][27][28]. Matera et al [25] compared the bronchodilating effects of salmeterol, albuterol, and ipratropium in a small group of patients (N=16) with stable COPD, and found that salmeterol was associated with a slower onset of action but a longer duration of effect than ipratropium.…”

“…Matera et al [25] compared the bronchodilating effects of salmeterol, albuterol, and ipratropium in a small group of patients (N=16) with stable COPD, and found that salmeterol was associated with a slower onset of action but a longer duration of effect than ipratropium. Salmeterol led to greater sustained improvements in mean FEV 1 from 4 to 12 hours after inhalation compared with ipratropium, whereas ipratropium resulted in greater mean changes in FEV 1 compared with salmeterol from 15 minutes to 1 hour after inhalation ( Table 3).…”